This website isn’t supported by Internet Explorer. We recommend that you use a different browser (e.g. Edge, Chrome, Firefox, Safari, or similar) for the best experience of our content.

  • El dispositivo con tecnología FlexTouch® contiene 300 unidades en total6
  • Permite la entrega de una dosis máxima de 80 unidades en 1 sola inyección6
  • Ajustes en la dosis desde 1 unidad6
  • Sin extensión del pulsador6

Fácil de usar: botón de dosis no extensible y baja fuerza de inyección, lo que significa una aplicación más fácil independientemente de la dosis.22-24,26


Confianza en la liberación de insulina: clic al final de la dosis para confianza del paciente y una entrega de dosis exacta.22-25


Preferido por los pacientes28

1.- Rodbard HW, Cariou B, Zinman B, et al. BEGIN Once Long trial investigators. Comparison of insulin degludec with insulin glargine in insulin- naive subjects with Type 2 diabetes: a 2-year randomized, treat-to-target trial. Diabet Med. 2013;30(11):1298-1304.

2.- Heise T, Hermanski L, Nosek L, et al. Insulin degludec: four times lower pharmacodynamic variability than insulin glargine under steady-state conditions in type 1 diabetes. Diabetes Obes Metab. 2012;14(9):859-864.

3.- Heise T, Nørskov M, Nosek L, et al. Insulin degludec: Lower day-to-day and within-day variability in pharmacodynamic response compared with insulin glargine 300 U/mL in type 1 diabetes. Diabetes Obes Metab. 2017;19(7):1032-1039.

4.- Marso SP, McGuire DK, Zinman B, et al. DEVOTE Study Group. Efficacy and Safety of Degludec versus Glargine in Type 2 Diabetes. N Engl J Med . 2017;377(8):723-732.

5.- Haahr H, Heise T. A Review of the Pharmacological Properties of Insulin Degludec and Their Clinical Relevance. Clin Pharmacokinet. 2014;53(9):787-800.

6.- Tresiba® Información Para Prescribir. 03.05.2018 (183300415U0022).

7.- Zinman B, Philis A, Cariou B, et al. NN12560-3579 (BEGIN Once Long) Trial Investigators. Insulin Degludec Versus Insulin Glargine in Insulin- Naive Patients With Type 2 Diabetes. Diabetes Care. 2012;35(12):2464-2471.

8.- Gough S, Bhargava A, Jain R, et al. Low-volume insulin degludec 200 units/ml once daily improves glycemic control similarly to insulin glargine with a low risk of hypoglycemia in insulin-naive patients with type 2 diabetes: a 26-week, randomized, controlled, multinational, treat-to-target trial: the BEGIN LOW VOLUME trial. Diabetes Care. 2013;36(9):2536-2542.

9.- Tibaldi J, Hadley-Brown M, Liebl A, et al. A comparative effectiveness study of degludec and insulin glargine 300 U/mL in insulin-naïve patients with typ 2 diabetes. Diabetes Obes Metab. 2018 Dec 15. doi:10.1111/dom.13616. [Epub ahead of print]

10.- Bode BW, Buse JB Fisher M, et al. BEGIN® Basal-Bolus Type 1 trial investigators. Insulin degludec improves glycaemic control with lowe nocturnal hypoglycaemia risk than insulin glargine in basal–bolus treatment with mealtime insulin aspart in Type 1 diabetes (BEGIN® Basal– Bolus Type 1): 2-year results of a randomized clinical trial. Diabet Med. 2013;30(11):1293-1297.

11.- Stratton IM, Adler AI, Neil HAW, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000;321(7258):405-412.

12.- Wakil A, Atkin SL. Insulin degludec—A new-generation basal insulin. Expert Opin Biol Ther. 2012;12(5):539-542.

13.- Heise T, Korsatko S, Nosek L, et al. Steady state is reached within 2–3 days of once-daily administration of degludec, a basal insulin with an ultralong duration of action. J Diabetes. 2016;8(1):132-138.

14.- Mathieu C, Gillard P, Benhalima K. Insulin analogues in type 1 diabetes mellitus: getting better all the time. Nat Rev Endocrinol. 2017;13(7):385-399.

15.- Kerlan V, Gouet D, Marre M, et al. Use of insulin degludec, a new basal insulin with an ultra-long duration of action, in basal–bolus therapy in type 1 and type 2 diabetes. Ann Endocrinol (Paris). 2013;74(5-6):487-490.

16.- Wang F, Surh J, Kaur M. Insulin degludec as an ultralong-acting basal insulin once a day: a systematic review. Diabetes Metab Syndr Obes. 2012;5:191-204.

17.- Tresiba Product Monograph.

18.- Heise T, Kaplan K, haahr HL. Day-to-Day and Within-Day Variability in Glucose-Lowering Effect Between Insulin Degludec and Insulin Glargine (100 U/mL and 300 U/mL): A Comparison Across Studies. J Diabetes Sci Technol. 2018;12(2):356-363.

19.- Jonassen Ib, Havelund S, Hoeg-Jensen T, et al. Design of the Novel Protraction Mechanism of Insulin Degludec, an Ultra-long-Acting Basal Insulin. Pharm Res. 2012;29(8):2104-2114.

20.- Novo Nordisk. [Internet] Novo Nordisk Receives FDA Approval fo Tresiba® (insulin degludec injection 100 U/mL, 200 U/mL) for Use in Children and Adolescentes With Diabetes. [Consultado el 10 de septiembre de 2019] Disponible en:,children%20and%20adolescents%20with%20diabetes.

21.- Thalange N, Deeb L, Iotova V, et al. Insulin degludec in combination with bolus insulin aspart is safe and effective in children and adolescents with type 1 diabetes. Pediatr Diabetes. 2015;16(3):164-176.

22.- Oyer D, Narendran P, Qvist M, et al. Ease of use and preference of a new versus widely available prefilled insulin pen assessed by people with diabetes, physicians and nurses. Expert Opin Drug Deliv. 2011;8(10):1259-1269.

23.- Bailey T, Thurman J, Niemeyer M, et al. Usability and preference evaluation of a prefilled insulin pen with a novel injection mechanism by people with diabetes and healthcare professionals. Curr Med Res Opin. 2011;27(10):2043-2052.

24.- Bailey T, Campos C. FlexTouch® for the delivery of insulin: technical attributes and perception among patients and healthcare professionals. Expert Rev Med Devices. 2012;9(3):209-217.

25.- Wielandt JO, Niemeyer M, Rye Hansen M, et al. FlexTouch: A Prefilled Insulin Pen with a Novel Injection Mechanism with Consistent High Accuracy at Low- (1 U), Medium- (40 U), and High- (80 U) Dose Settings. J Diabetes Sci Technol. 2011;5(5):1195-1199.

26.- Hemmingsen H, Niemeyer M, Hansen MR, et al. A prefilled insulin pen with a novel injection mechanism and a lower injection force than other prefilled insulin pens. Diabetes Technol Ther. 2011;13(12):1207-1211.

27.- Nadeau DA, Campos C, Niemeyr M, et al. Healthcare professional and patient assessment of a new prefilled insulin pen versus two widely available prefilled insulin pens for ease of use, teaching and learning. Curr Med Res Opin. 2012;28(1): 3-13.

28.- Philis-Tsimikas A, Brod M, Niemeyer M, et al. Insulin degludec once-daily in type 2 diabetes: simple or step-wise titration (BEGIN: oncesimple use). Adv Ther. 2013;30(6):607-622.

29.- Patel HB. Utilization of Novel Basal Insulin Therapies for Patients with Type 2 Diabetes Mellitus. Lones Star Pharmacist. Article Abstract.

30.- Mathieu C, Hollander P, Miranda-Palma B, et al. NN1250-3770 (BEGIN: Flex T1) Trial Investigators. Efficacy and Safety of Insulin Degludec in a Flexible Dosing Regimen vs Insulin Glargine in Patients With Type 1 Diabetes (BEGIN: Flex T1): A 26-Week Randomized, Treat-to-Target Trial With a 26-Week Extension. J Clin Endocrinol Metab. 2013;98(3):1154-1162.

31.- Lewis J. New Therapies for Patients With Type 2 Diabetes. PharmacyTime. 2017.

32.- Tresiba. [Package insert] Plainsboro, NJ: Novo Nordisk Inc; November 2018.

33.- Meneghini L, Atkin SL, Gough SC, et al. NN1250-3668 (BEGIN FLEX) Trial Investigators. The Efficacy and Safety of Insulin Degludec Given in Variable Once-Daily Dosing Intervals Compared With Insulin Glargine and Insulin Degludec Dosed at the Same TimeDaily. A 26-week, randomized, open-label, parallel-group, treat-to-target trial in individuals with type 2 diabetes. Diabetes Care. 2013;36(4):858-864.

34.- Khunti K, Alsifri S, Aronson R, et al. HAT Investigator Group. Rates and predictors of hypoglycaemia in 27 585 people from 24 countries with insulin-treated type 1 and type 2 diabetes: the global HAT study. Diabetes Obes Metab. 2016;18(9):907-915.

35.- Ratner RE, Gough SCL, Mathieu C, et al. Hypoglycaemia risk with insulin degludec compared with insulin glargine in type 2 and type 1 diabetes: a pre-planned meta-analysis of phase 3 trials. Diabetes Obes Metab. 2013;15(2):175-184.

36.- Philis-Tsimikas, A., Klonoff, D.C., Khunti, K. et al. Risk of hypoglycaemia with insulin degludec versus insulin glargine U300 in insulin-treated patients with type 2 diabetes: the randomised, head-to-head CONCLUDE trial. Diabetologia (2020).

37.- Fadini GP., Feher M., Hansen TK, et al. Switching to Degludec From Other Basal Insulins Is Associated With Reduced Hypoglycemia Rates: A Prospective Study. J Clin Endocrinol Metab, December 2019, 104(12):5977–5990.